Director Allen Patricia L bought 19,860 shares at blended average $25.16, totaling $499,745.60 on Feb 12-13, marking first purchase post-zero holding; cluster of 2 other insider buys in past 14 days
Director Allen Patricia L executed 4 separate purchases totaling 19,860 shares for $499,745.60 at prices ranging from $23.77 to $26.50, establishing a position from zero shares. The blended average price of $25.16 sits 4.7% below the current price of $26.40 and 38.4% below the 52-week high of $43.17. This purchase coincides with a cluster pattern where 2 other insiders also bought within the past 14 days, suggesting coordinated board-level accumulation. However, ZBIO faces significant headwinds: the company reported zero revenue in the latest quarter, a $-51,499,000 net loss over its most recent full fiscal year, and annual revenue contraction of -90.0%, indicating severe operational deterioration. The stock has declined -24.6% over the past 90 days despite recent insider buying activity, raising the question of whether director accumulation reflects conviction or routine portfolio activity in a distressed biotech environment.